156 related articles for article (PubMed ID: 10744050)
1. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol in rat hepatoma AH-109A cells and human tumor cell lines.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 Apr; 23(4):487-91. PubMed ID: 10784433
[TBL] [Abstract][Full Text] [Related]
4. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol.
Kishimoto S; Ohtani A; Fukuda H; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2003 May; 26(5):683-6. PubMed ID: 12736512
[TBL] [Abstract][Full Text] [Related]
5. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 May; 23(5):637-40. PubMed ID: 10823679
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 Mar; 23(3):344-8. PubMed ID: 10726891
[TBL] [Abstract][Full Text] [Related]
7. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T; Chiba N; Nishikaku F
Cancer Chemother Pharmacol; 2009 Aug; 64(3):473-83. PubMed ID: 19104812
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol.
Fujiyama S; Shibata J; Maeda S; Tanaka M; Noumaru S; Sato K; Tomita K
Br J Cancer; 2003 Nov; 89(9):1614-9. PubMed ID: 14583758
[TBL] [Abstract][Full Text] [Related]
10. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
11. Long-term disposition of a novel lipophilic platinum complex SM-11355 in dog after intrahepatic arterial administration: highly sensitive detection of platinum and radioactivity.
Shimakura J; Fujimoto K; Komuro S; Nakano M; Kanamaru H
Xenobiotica; 2002 May; 32(5):399-409. PubMed ID: 12065062
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
13. Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.
Takahashi I; Maehara Y; Kusumoto H; Kohnoe S; Sugimachi K
Cancer Chemother Pharmacol; 1993; 33(1):31-5. PubMed ID: 8269586
[TBL] [Abstract][Full Text] [Related]
14. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
Kishimoto S; Yasuda M; Suzuki R; Fukushima S
Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
[TBL] [Abstract][Full Text] [Related]
15. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]